Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans

Journal of Endocrinology

Volumn 216, Issue 2, 2013, Pages 135-143

  Kralisch, Susan ^a,b   Tönjes, Anke ^a,b   Krause, Kerstin ^a   Richter, Judit ^a,b   Lossner, Ulkrike ^a,b   Kovacs, Peter ^a   Ebert, Thomas ^a   Blüher, Matthias ^a,b   Stumvoll, Michael ^a,b   Fasshauer, Mathias ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

FGF21; IGF1; Insulin resistance; Liver; Obesity; Sorbs

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR; SOMATOMEDIN C;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ENDOCRINE FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT MASS; FEMALE; GLOMERULUS FILTRATION RATE; HIP CIRCUMFERENCE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; LIMIT OF DETECTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; CELL STRAIN HEPG2; LIVER; PHYSIOLOGY;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTORS; HEP G2 CELLS; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIVER; PHENOTYPE;

MLCS; MLOWN;

EID: 84874767867     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0367     Document Type: Article

References (42)

1. American Diabetes Association 2010 Diagnosis and classification of diabetes mellitus
2. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS & Maratos-Flier E 2007 Hepatic fibroblast growth factor 21 is regulated by PPARa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 5 426-437.
3. Beenken A & Mohammadi M 2009 The FGF family: biology, pathophysiology and therapy. Nature Reviews. Drug Discovery 8 235-253.
4. Cantó C & Auwerx J 2012 FGF21 takes a fat bite. Science 336 675-676.
5. Chen C, Cheung BMY, Tso AWK, Wang Y, Law LSC, Ong KL, Wat NMS, Xu A & Lam KSL 2011 High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes. Diabetes Care 34 2113-2115.
6. Chu JW, Abbasi F, Beatty GW, Khalili M, Koch J, Rosen A, Schmidt JM, Stansell JD & Reaven GM 2003 Methods for quantifying insulin resistance in human immunodeficiency virus-positive patients. Metabolism 52 858-861.
7. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE & Kharitonenkov A 2008 Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149 6018-6027.
8. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML & Maratos-Flier E 2010 Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139 456-463.
9. Fazeli PK, Misra M, Goldstein M, Miller KK & Klibanski A 2010 Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 95 369-374.
10. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS & Maratos-Flier E 2010 Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59 2781-2789.
11. Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, Moon MK, Lee HK, Kang SW, Han DS et al. 2010 Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in endstage renal disease patients receiving long-term peritoneal dialysis. Metabolism 59 1656-1662.
12. Iglesias P, Selgas R, Romero S & Díez JJ 2012 MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. European Journal of Endocrinology 167 301-309.
13. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V et al. 2007 Endocrine regulation of the fasting response by PPARa-mediated induction of fibroblast growth factor 21. Cell Metabolism 5 415-425.
14. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ & Kliewer SA 2008 Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metabolism 8 77-83.
15. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA et al. 2005 FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 115 1627-1635.
16. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB & Etgen GJ 2007 The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148 774-781.
17. Kralisch S & Fasshauer M 2011 Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease. Current Opinion in Clinical Nutrition & Metabolic Care 14 354-359.
18. Kubicky RA, Wu S, Kharitonenkov A & De Luca F 2012 Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice. Endocrinology 153 2287-2295.
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al. 2009 A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 150 604-612.
20. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K et al. 2010 Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology 53 934-940.
21. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, FengW& Li X 2010 Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE 5 e15534.
22. Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, Wang X, Lin S, FengW& Li X 2011 Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE 6 e18398.
23. Lin Z, Gong Q, Wu C, Yu J, Lu T, Pan X, Lin S & Li X 2012 Dynamic change of serum FGF21 levels in response to glucose challenge in human. Journal of Clinical Endocrinology and Metabolism 97 E1224-E1228.
24. Mai K, Bobbert T, Groth C, Assmann A, Meinus S, Kraatz J, Andres J, Arafat AM, Pfeiffer AF, Mohlig M et al. 2010 Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. American Journal of Physiology. Endocrinology and Metabolism 299 E126-E130.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC 1985 Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 412-419.
26. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV, Mohammadi M & Kuro-o M 2007 bKlotho is required for metabolic activity of fibroblast growth factor 21. PNAS 104 7432-7437.
27. Reinehr T, Woelfle J, Wunsch R & Roth CL 2012 Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. Journal of Clinical Endocrinology and Metabolism 97 2143-2150.
28. Semba RD, Sun K, Egan JM, Crasto C, Carlson OD & Ferrucci L 2012 Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore longitudinal study of aging. Journal of Clinical Endocrinology and Metabolism 97 1375-1382.
29. Shen J, Chan HL-Y, Wong GL-H, Choi PC-L, Chan AW-H, Chan H-Y, Chim AM-L, Yeung DK-W, Chan FK-L, Woo J et al. 2012 Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of Hepatology 56 1363-1370.
30. Stein S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M & Fasshauer M 2009 Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32 126-128.
31. Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, Drynda K, Lossner U, Bluher M, Stumvoll M & Fasshauer M 2010 Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 59 33-37.
32. Stumvoll M, Van Haeften T, Fritsche A & Gerich J 2001 Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care 24 796-797.
33. Tonjes A, Koriath M, Schleinitz D, Dietrich K, Bottcher Y, Rayner NW, Almgren P, Enigk B, Richter O, Rohm S et al. 2009 Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs. Human Molecular Genetics 18 4662-4668.
34. Tonjes A, Zeggini E, Kovacs P, Bottcher Y, Schleinitz D, Dietrich K, Morris AP, Enigk B, Rayner NW, Koriath M et al. 2010 Association of FTO variants with BMI and fat mass in the self-contained population of Sorbs in Germany. European Journal of Human Genetics 18 104-110.
35. Tonjes A, Kralisch S, Lossner U, Kovacs P, Bluher M, Stumvoll M & Fasshauer M 2012 Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein. International Journal of Obesity 36 766-773.
36. Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J, Rissanen A, Suomalainen A & Pietilainen KH 2010 Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. Journal of Clinical Endocrinology and Metabolism 96 E351-E355.
37. Wang H, Qiang L & Farmer SR 2008 Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Molecular and Cellular Biology 28 188-200.
38. Wu S, Levenson A, Kharitonenkov A & De Luca F 2012 Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone (GH) action directly at the growth plate. Journal of Biological Chemistry 287 26060-26067.
39. Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M, Rao S, Yao X, Tu Y, Jia W et al. 2011 Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS ONE 6 e24895.
40. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C & Avsar E 2010 Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. European Journal of Clinical Investigation 40 887-892.
41. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M & Ornitz DM 2006 Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. Journal of Biological Chemistry 281 15694-15700.
42. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS et al. 2008 Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57 1246-1253.